Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$115.82

-0.37 (-0.32%)

08:02
04/21/17
04/21
08:02
04/21/17
08:02

GW Pharmaceuticals initiated with a Buy at Maxim

Maxim analyst Lauren Chung initiated GW Pharmaceuticals with a Buy rating and $135 price target, calling the company the "market leader" in cannabis therapeutics with a first-mover advantage in epilepsy.

GWPH GW Pharmaceuticals
$115.82

-0.37 (-0.32%)

12/05/16
CANT
12/05/16
NO CHANGE
Target $208
CANT
Buy
GW Pharmaceuticals price target raised after Epidiolex data at Cantor
Cantor analyst Elemer Piros raised his price target for GW Pharmaceuticals to $208 from $182 following its Epidiolex data presented at the American Epilepsy Society meeting. The analyst believes the data illustrates "robustness and remarkable consistency" across two distinct forms of epilepsy, Lennox Gastaut and Dravet syndrome and notes that the company laid to rest the largely overblown concern regarding drug interaction with clobazam. Piros believes GW Pharmaceuticals is in "good shape" for a New Drug Application covering both indications by the end of 1H17, and reiterates a Buy rating on the shares.
02/07/17
CANT
02/07/17
NO CHANGE
Target $208
CANT
Overweight
GW Pharmaceuticals Phase 2 data 'very encouraging,' says Cantor
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals' Phase 2 glioblastoma multiforme data today are "very encouraging" and further support of the "multi-potent effect of cannabinoid-based medicines across an array of neurological condition." The analyst reiterates a Buy rating on GW shares with a $208 price target. The stock in early trading is up 93c to $121.69.
02/07/17
PIPR
02/07/17
NO CHANGE
Target $147
PIPR
Overweight
Piper says GW Pharmaceuticals remains on track with Epidiolex
Piper Jaffray analyst Joshua Schimmer said GW Pharmaceuticals remains on track to potentially launch Epidiolex for Dravet Syndrome and LGS in the first half of 2018 and he sees the company's expanded access program and ongoing trials positioning the product for a "robust launch" upon approval. Retention of patients on therapy remains "exceptionally high," added the analyst, who calls GW a top mid-cap pick citing his confidence in the commercial outlook for Epidiolex and optimism about its pipeline. Schimmer keeps an Overweight rating and $147 price target on GW Pharma shares.
03/02/17
JANY
03/02/17
NO CHANGE
Target $55
JANY
Sell
GW Pharmaceuticals expectations, valuation remain too high, says Janney Capital
Janney Capital analyst Ken Trbovich raised his estimates for GW Pharmaceuticals and increased his fair value estimate for the shares to $55, citing the "excitement" he heard among physicians who regularly treat patients with Epidiolex during the Annual Epilepsy Society meeting last December. However, he continues to think regulatory and commercial challenges will likely prevent Epidiolex from achieving high expectations set by the market, even if the drug is approved on first review for Dravet Syndrome and LGS and the subsequent studies in infantile spasm and tuberous sclerosis succeed. Trbovich, who notes that consensus estimates call for Epidiolex to hit $900M in sales in just 3-4 years even though the most recent FDA-approved drugs for orphan epilepsy indications had sales in the range of $100M-$300M 4-8 years after launch, keeps a Sell rating on GW shares.

TODAY'S FREE FLY STORIES

CNMD

CONMED

$48.13

0.93 (1.97%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Recommendations
CONMED analyst commentary  »

CONMED price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

ALKS

Alkermes

$57.13

0.13 (0.23%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Hot Stocks
Alkermes says NDA for ALKS 5461 on track for this year »

Alkermes says it is on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

  • 08

    Jun

MGM

MGM Resorts

$29.79

0.44 (1.50%)

08:45
04/27/17
04/27
08:45
04/27/17
08:45
Hot Stocks
MGM Resorts reports MGM China revenues up 7% to $502M »

Key first quarter results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

08:45
04/27/17
04/27
08:45
04/27/17
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

AAL

American Airlines

$46.40

-0.21 (-0.45%)

08:44
04/27/17
04/27
08:44
04/27/17
08:44
Technical Analysis
American Airlines trades down after earnings, downgrade »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WSM

Williams-Sonoma

$54.66

0.03 (0.05%)

08:43
04/27/17
04/27
08:43
04/27/17
08:43
Hot Stocks
Williams-Sonoma launches food collaboration with Trisha Yearwood »

Williams Sonoma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

08:43
04/27/17
04/27
08:43
04/27/17
08:43
Recommendations
F5 Networks analyst commentary  »

F5 Networks should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPWR

Monolithic Power

$93.71

-2.5 (-2.60%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Recommendations
Monolithic Power analyst commentary  »

Monolithic Power price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.87

-0.1399 (-6.96%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
Cellectar says radiotherapeutic PDCS demonstrates increased survival benefit »

Cellectar Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.79

0.44 (1.50%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Earnings
MGM Resorts reports Q1 EPS 36c, consensus 29c »

Reports Q1 revenue less…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DLX

Deluxe

$71.85

0.26 (0.36%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Earnings
Deluxe narrows FY17 EPS view to $5.15-$5.30 from $5.10-$5.30, consensus $5.21 »

Narrows FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

ALKS

Alkermes

$57.13

0.13 (0.23%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
Alkermes sees FDA meeting on ALKS 5461 in late June, early July »

Alkermes said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

  • 08

    Jun

UPS

UPS

$107.62

0.26 (0.24%)

08:42
04/27/17
04/27
08:42
04/27/17
08:42
Hot Stocks
UPS says plans to announce additional strategic moves in coming weeks »

Comments from Q1 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

RMTI

Rockwell Medical

$8.64

0.28 (3.35%)

08:41
04/27/17
04/27
08:41
04/27/17
08:41
Hot Stocks
Rockwell Medical to present on Triferic at Congress of IBIS »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDSO

Medidata

$67.14

3.8 (6.00%)

08:41
04/27/17
04/27
08:41
04/27/17
08:41
Recommendations
Medidata analyst commentary  »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

TEUM

Pareteum

$0.71

0.0084 (1.20%)

08:40
04/27/17
04/27
08:40
04/27/17
08:40
Hot Stocks
Pareteum's cloud platform selected by THYNGS »

Pareteum's Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$71.85

0.26 (0.36%)

08:40
04/27/17
04/27
08:40
04/27/17
08:40
Earnings
Deluxe sees Q3 adj. EPS $1.20-$1.25 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

08:40
04/27/17
04/27
08:40
04/27/17
08:40
General news
U.S. initial jobless claims rose 14k »

U.S. initial jobless…

DLX

Deluxe

$71.85

0.26 (0.36%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Earnings
Deluxe sees Q2 adj. EPS $1.23-$1.28, consensus $1.24 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

TWTR

Twitter

$15.82

1.16 (7.91%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Recommendations
Twitter analyst commentary  »

Twitter ad revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SINO

Sino-Global

$3.03

0.08 (2.71%)

08:39
04/27/17
04/27
08:39
04/27/17
08:39
Hot Stocks
Sino-Global signs cooperation agreement with Ningbo Xinyang Shipping »

Sino-Global signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$71.85

0.26 (0.36%)

08:38
04/27/17
04/27
08:38
04/27/17
08:38
Earnings
Deluxe reports Q1 EPS $1.25, consensus $1.15 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

DGLY

Digital Ally

$4.25

0.25 (6.25%)

08:37
04/27/17
04/27
08:37
04/27/17
08:37
Hot Stocks
Digital Ally receives order for airport shuttle bus fleet video systems upgrade »

Digital Ally announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKS

Barnes & Noble

$8.90

0.1 (1.14%)

08:36
04/27/17
04/27
08:36
04/27/17
08:36
Hot Stocks
Barnes & Noble appoints Demos Parneros to CEO »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVI

CVR Energy

$19.69

-0.63 (-3.10%)

08:36
04/27/17
04/27
08:36
04/27/17
08:36
Earnings
CVR Energy reports Q1 EPS 26c, consensus (5c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.